Organogenesis Holdings (ORGO) Operating Expenses (2016 - 2026)

Organogenesis Holdings has reported Operating Expenses for 11 years, with the latest figure at $94.7 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 16.58% year-over-year to $94.7 million in Q2 2026; TTM through Jun 2026 was $493.3 million, a 9.05% increase from a year earlier, with the FY2025 full-year figure at $519.5 million, up 7.48% from the prior year.
• Operating Expenses was $94.7 million for Q2 2026 at Organogenesis Holdings, down from $106.1 million in the prior quarter.
• The five-year high for Operating Expenses was $179.6 million in Q4 2023, with the low at $72.2 million in Q1 2022.
• Average Operating Expenses over 5 years is $106.6 million, with a median of $100.4 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 125.42% in 2023, then sank 35.18% in 2024.
• Over 5 years, Operating Expenses stood at $79.7 million in 2022, then soared by 125.42% to $179.6 million in 2023, then slumped by 35.18% to $116.4 million in 2024, then soared by 39.4% to $162.3 million in 2025, then sank by 41.63% to $94.7 million in 2026.
• The last three Operating Expenses figures came in at $94.7 million (Q2 2026), $106.1 million (Q1 2026), and $162.3 million (Q4 2025), per Business Quant data.